Videos

Jake Glaser shares what is needed to achieve the Fast-Track strategy to end the AIDS epidemic by 2030.

Richard Haupt, MD, MPH, explains how a vaccine can serve as a primary prevention modality against C. difficile.

Daniel Diekema, MD, discusses the different roles that clinical laboratories play in outbreak response.

William Schaffner, MD, offers insight into the 2017-2018 flu season, including which strain of the virus that is expected to be most prevalent.

Leonard Sigal, MD, discusses different causes of persisting symptoms after Lyme disease infection.

Richard Haupt, MD, MPH, explains why a vaccine to help prevent C. difficile is so needed.

Michael Edmond, MD, MPH, MPA, explains how health care facilities can work on preparing for the unexpected in the realm of infectious diseases.

Edmond Hooker, MD, DrPH, explains why hospital mattresses are harder to disinfect than other harder surfaces.

Daniel Diekema, MD, explains why microbiology labs should be seen as an integral part of antimicrobial stewardship efforts.

William Schaffner, MD, lists some of the common reasons behind why individuals decide against getting their flu shots, and why they should reconsider.

Robert Bransfield, MD, DLFAPA, explains how he was able to establish a correlation between suicidal risk and Lyme disease.

Richard Haupt, MD, MPH, explains the risk factors for Clostridium difficile infection.

Paul Feuerstadt, MD, sheds light on the estimated burden of C. difficile infection in the United States.

Norman B. Javitt, MD, PhD, explains how antibiotics can impact bile acid composition and result in Clostridium difficile infection.

Barley Chironda, RPN, CIC, discusses current infection control measures taken to prevent C. difficile and the reasons why they are falling short.

Joe Sliman, MD, MPH, explains how antibiotics affect the gut microbiome.

Glenn Tillotson, PhD, FIDSA, discusses the societal value of antibiotics.

Sahil Khanna, MBBS, MS, provides a brief overview of the history of fecal microbiota transplantation.

Stuart Johnson, MD, discusses the disadvantages to some of the current approaches used to treat C. difficile.

James S. Lewis, PharmD, FIDSA, explains how pharmacists can advocate for judicious antibiotic use in patients through educating the patients themselves, as well as providers.

Ferric Fang, MD, explains the major challenges associated with diagnosing Clostridium difficile infection.

Roy F. Chemaly, MD, MPH, discusses the background behind letermovir and what it brings to the table.

Dale N. Gerding, MD, discusses different methods used to prevent CDI recurrence.

Edmond Hooker, MD, DrPH, discusses multiple factors that put patients at increased risk of getting C. difficile.

Robert Bransfield, MD, DLFAPA, shares different symptoms caused by Lyme disease, which could, in turn, result in psychiatric conditions that increase the risk of self-harm or harming others in some patients.

James S. Lewis, PharmD, FIDSA, discusses the need for the development of non-antibacterial options against infections, such as monoclonal antibodies.

Daniel Diekema, MD, explains how the microbiology lab works to provide optimal drug selection for empiric and directed therapy.

Michael Edmond, MD, MPH, MPA, explains current challenges faced by hospital epidemiologists.